

Novocure Ltd  
Form 8-K  
November 20, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 17, 2015**

**NovoCure Limited**

**(Exact name of registrant as specified in its charter)**

**Jersey (Channel Islands)**  
**(State or other jurisdiction**

**of incorporation)**

**001-37565**  
**(Commission**

**File Number)**

**Not Applicable**  
**(IRS Employer**

**Identification No.)**

**Le Masurier House**

**La Rue Le Masurier**

**St. Helier, Jersey**

**(Address of principal executive offices)**

**JE2 4YE**

**(Zip Code)**

**Registrant's telephone number, including area code: +44 (0)15 3475 6700**

**N/A**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. to Form 8-K):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

The press releases of NovoCure Limited, two dated November 17, 2015 and one dated November 20, 2015, are filed herewith as Exhibits 99.1, 99.2 and 99.3.

**Item 9.01 Financial Statements and Exhibits**

*(d) Exhibits*

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of NovoCure Limited, dated November 17, 2015
99.2	Press Release of NovoCure Limited, dated November 17, 2015
99.3	Press Release of NovoCure Limited, dated November 20, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NovoCure Limited**

(Registrant)

Date: November 20, 2015

By: /s/ Wilco Groenhuysen

Name: Wilco Groenhuysen

Title: Chief Financial Officer

**Index to Exhibits**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of NovoCure Limited, dated November 17, 2015
99.2	Press Release of NovoCure Limited, dated November 17, 2015
99.3	Press Release of NovoCure Limited, dated November 20, 2015